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Introduction: The purpose of this study was to evaluate whether 
consolidation chemotherapy (CCT) after concurrent chemo-radio-
therapy is beneficial for patients with locally advanced non–small-
cell lung cancer (LA-NSCLC).
Methods: We systematically searched PubMed for phase II/III tri-
als published before December 31, 2011, examining survival of 
LA-NSCLC treated with concurrent chemo-radiotherapy. Median 
overall survival and other study characteristics were collected from 
each study and pooled. We extracted log-transformed hazards and 
standard errors under the assumption that survival follows an expo-
nential distribution, and computed a pooled median overall survival 
and a 95% confidence interval (CI) using random-effects model. 
Collected trial arms were categorized as having CCT or not having it, 
CCT+ and CCT−, respectively.
Results: Forty-one studies were identified including seven phase III 
studies and 34 phase II studies with 45 arms (CCT+: 25; CCT−: 20). 
Clinical data were comparable for clinical stage, performance sta-
tus, cancer histology, sex, and median age between the two groups. 
There was no statistical difference in pooled mOS between CCT+ 
(19.0 month; 95% CI, 17.3−21.0) and CCT− (17.9 month; 95% CI, 
16.1−19.9). Predicted hazard ratio of CCT+ to CCT− was 0.94 (95% 
CI, 0.81−1.09; p = 0.40). There were no differences between the two 
groups with regard to grade 3−5 toxicities in pneumonitis, esopha-
gitis, and neutropenia. These models estimated that addition of CCT 
could not lead to significant survival prolongation or risk reduction 
in death for LA-NSCLC patients.
Conclusion: The pooled analysis based on a publication basis failed 
to provide evidence that CCT yields significant survival benefit for 
LA-NSCLC.
Key Words: Non–small-cell lung cancer, Chemo-radiotherapy, 
Consolidation chemotherapy, Locally advanced.
(J Thorac Oncol. 2013;8: 1181-1189)
Lung cancer continues to be the leading cause of cancer-related deaths worldwide, with approximately 1.4 mil-
lion deaths per year.1 Non–small-cell lung cancer (NSCLC) 
represents more than 80% of all lung tumors, and approxi-
mately 35% of patients with NSCLC present with stage 
III locally advanced non–small cell lung cancer disease 
(LA-NSCLC). Previous clinical trials of LA-NSCLC dem-
onstrated that concurrent administration of two cycles of 
chemotherapy with thoracic radiotherapy (TRT) improved 
overall survival (OS) compared with radiotherapy (RT) 
alone and/or sequential chemo-RT.2–4 Thus the standard 
treatment for patients with LA-NSCLC is recognized as 
concurrent chemo-RT with curative intent. Despite recent 
progress, cure rates remain low for those diagnosed with 
LA-NSCLC, and the prognosis for the vast majority of 
LA-NSCLC patients still remains poor. Therefore, new 
strategies such as radiation methods, radiation dose, optimal 
chemotherapy regimen, prophylactic cranial irradiation, 
and molecular targeted agents, are needed to improve clini-
cal outcome.5 The addition of consolidation chemotherapy 
(CCT) is another attractive approach.
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Recently, close attention has been paid to the efficacy of 
maintenance chemotherapy after platinum combination che-
motherapy for metastatic NSCLC patients and postoperative 
adjuvant chemotherapy for early-stage NSCLC patients. In 
fact, several randomized studies and their systematic reviews/
meta-analyses have already indicated the efficacy of main-
tenance6,7 and adjuvant chemotherapy.8–10 For LA-NSCLC 
patients, however, little is known about the efficacy of CCT 
and few randomized studies have been reported. The Hoosier 
Oncology Group recently performed a randomized phase III 
study and reported that CCT with docetaxel increased toxici-
ties without significant survival benefit.11 There is currently 
insufficient evidence indicating CCT improves OS of patients 
with LA-NSCLC.
The purpose of this study is to evaluate, through a 
pooled analysis of publications, whether CCT after concur-
rent chemo-RT is beneficial for patients with LA-NSCLC in 
terms of survival prolongation.
MATERIALS AND METHODS
Literature Search and Data Extraction
We performed a systematic search of PubMed for phase 
II/III trials examining survivals of LA-NSCLC patients treated 
with concurrent chemo-RT. All trials that had been reported 
by December 31, 2011, were targeted. Systematic search was 
performed using the key words, non-small cell lung cancer, 
radiation or RT, concurrent or concomitant, phase II or phase 
III. All searches were limited to English language and studies 
with no less than 30 patients per arm. Chemotherapy regimens 
scheduled in the concurrent phase were limited to platinum 
combination therapies. When a study had multiple arms and 
at least one of them fulfilled the requirements, it was included 
in our analysis. Studies that did not analyze survival data, or 
that analyzed only patients with poor performance status (PS; 
Eastern Cooperative Oncology Group score ≥ 2/Karnofsky 
score ≤ 70) or high-risk complications, or elderly patients (age 
≥ 70 years) were excluded. Studies, in which randomization 
and survival analyses were performed only on patients with no 
disease progression after induction chemo-RT were excluded 
because these trials would strongly be biased toward longer OS. 
We also excluded trial arms in which surgery or induction che-
motherapy was offered in addition to the concurrent chemo-RT.
Collected trial arms were categorized as having (CCT+) 
or not having (CCT−) CCT. We defined CCT as systemic che-
motherapy sequentially performed after concurrent chemo-
RT. Arms, in which triweekly carboplatin plus paclitaxel 
were used after low-dose weekly carboplatin plus paclitaxel 
with concurrent TRT, were included in CCT+ group in this 
analysis. CCT+ group was further divided into two patterns 
of CCT: continuous CCT (CCCT), which continues treatment 
with at least one of the agents given in the initial therapy and 
switch CCT (SCCT), which switches to a different agent. For 
each trial, data on sample size, OS, chemotherapy regimens, 
doses of RT, delivery of treatment, frequency of grade 3−5 
toxicities (neutropenia, leukopenia, esophagitis, pneumonitis, 
and treatment-related death) were collected. Median OS, and 
1-, 2-, and 3-year OS rates were determined using reported 
data or survival curves. We also recorded data of patient 
characteristics included in studies (age, sex, histology and 
stage of cancer, and PS) and study characteristics (trial phase, 
chemotherapy regimen, and period and region in which study 
was conducted) to assess heterogeneity across studies.
All phase II/III studies were retrieved independently 
by two investigators (KT and SY) to assess the reliability of 
data extraction. After selection of potentially appropriate tri-
als, the investigators reviewed each other’s selected trials and 
excluded inappropriate trials with the agreement of both. 
Disagreements were adjudicated by a third reviewer after 
referring to the original articles.
Statistical Analysis
To estimate 95% confidence interval (CI) for median 
(mOS), the observed mOS was considered as an approxi-
mate estimate of the median of an exponential distribution. To 
examine the bias and validity of this estimation, we compared 
measured and estimated values of 1-, 2-, and 3-year survival 
rates and calculated the discrepancy among them by mean 
prediction error and root mean squared error.12,13
For each study, hazard was calculated as the natural loga-
rithm of 2 divided by the mOS. We combined log-transformed 
hazards and standard errors (SEs) from individual studies and 
computed a pooled mean and SE of the log-transformed haz-
ard using a random-effects model. Comparison of the pooled 
survival between CCT− and CCT+ was performed by meta-
regression analysis. Because two study characteristics, region 
and period, were found to be associated with survival, we 
performed additional meta-regression analysis adjusted for 
them. Pooled mOS with 95% CI was calculated as the natural 
logarithm of 2 divided by the pooled hazard, which was con-
verted back from the pooled log-transformed value computed 
in the random-effects model. Hazard ratio (HR) was obtained 
by taking the ratio of the pooled hazards estimated in the 
meta-regression analysis. The I2 statistics were used to assess 
heterogeneity across studies, and I2 less than 25, I2 of 25 or 
more, but less than 50, and I2 of 50 or more were interpreted 
as signifying low-level, intermediate-level, and high-level 
heterogeneity, respectively.14 The survival benefit of CCT was 
analyzed in all studies, and also in subgroups according to 
study character using a forest plot of HRs. We used Student’s t 
test, Kruskal–Wallis test, or Pearson’s χ2 test to examine a dif-
ference in the distribution of targeted values among trial arms, 
or in the proportion of targeted trial arms.
A p value less than 0.05 was considered statistically 
significant, and all reported p values were two-sided. The 
Eggers’ test and Begg’s funnel plots were calculated using 
Comprehensive Meta-Analysis version 2 (Biostat Inc., 
Englewood, NJ). All other statistical analyses were performed 
using SPSS 17.0 (SPSS Inc., Chicago, IL) or SAS version 9 
(SAS Inc., Cary, NC).
RESULTS
Patient Characteristics and Treatment 
Administrations in Each Study
We identified 41 studies2,4,15–53 (7 phase III studies 
and 34 phase II studies) including 45 arms with 3479 
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patients, which examined survivals of LA-NSCLC 
patients treated with concurrent chemo-RT (Fig. 1; and 
Supplementary Table 1, Supplemental Digital Content 1, 
http://links.lww.com/JTO/A439). All 41 studies repor-
ted mature data on mOS and 1-year OS, whereas 40 
studies reported data on 2-year OS, and 32 studies did on 
3-year OS.
Among studies analyzed, 25 arms (1707 patients) were 
designed to perform CCT after concurrent chemo-RT (CCT+ 
group), whereas 20 arms (1772 patients) were designed for 
only concurrent chemo-RT (CCT− group). In CCT+ group, 
four arms (247 patients) were designed for SCCT and other 21 
arms (1460 patients) for CCCT. The data on included patients 
and administered treatments of the two groups are shown in 
Table 1. There was no statistical difference between the two 
groups in clinical data of included patients, such as age, sex, 
histology and clinical stage of cancer, and PS. The planned 
doses of TRT were comparable between the two groups 
(62−63 Gy on average in both groups; Table 1). In concur-
rent phases, approximately 80% to 90% of patients had com-
pleted RT/chemotherapy in both groups. Regarding CCT, 1 to 
4 (average: 2.3) cycles had been planned in CCT+ arms, and 
among them, 0.7 to 3.1 (average: 1.5) cycles were actually 
delivered (Table 1).
FIGURE 1.  Flowchart showing retrieved citations from 
literature searches and the number of trials analyzed. NSCLC, 
non–small-lung cancer; PS, performance status.
TABLE 1.  Differences of Patient Characteristics and Treatment Administrations between Study Arms with and without CCT
Arms without CCT Arms with CCT
Patients Characteristics Mean SD Mean SD pa
Age
  Median age 61.71 2.72 60.58 3.24 0.22
Sex
  Female, % 21.96 12.54 23.79 12.92 0.63
Histology
  Squamous cell carcinoma, % 47.56 9.94 43.67 12.20 0.26
  Adenocarcinoma, % 35.60 8.85 36.02 12.51 0.90
Stage
  IIIA, % 35.68 19.21 33.19 18.35 0.67
  IIIB, % 63.27 19.29 66.31 18.61 0.52
PS, %b
  0 46.43 25.72 42.89 19.94 0.65
  1 50.38 21.70 52.92 16.01 0.70
  2 4.28 6.97 4.36 11.48 0.98
Treatment Administrations
Concurrent phase
  Planned TRT dose (Gy) 62.85 5.99 62.70 3.50 0.96
  Patients who completed TRT (%) 85.65 10.89 89.18 7.66 0.29
  Patients who completed 
chemotherapies (%)
86.15 13.03 79.16 14.47 0.14
Consolidation phase
  No. of planned CCT cycles — — 2.32 0.90 —
  Median no. of delivered CCT cycles — — 1.88 0.90 —
  Mean no. of delivered CCT cycles — — 1.53 0.64 —
aStatistical differences were calculated using Student’s t test across trial arms.
bKPS was converted to Eastern Cooperative Oncology Group PS as follows: KPS 90–100; PS 0, KPS 70–80; PS 1, KPS 60–70; PS 2.
TRT, thoracic radiotherapy; CCT, consolidation chemotherapy; PS, performance status; SD, standard deviation; KPS, Karnofsky performance score.
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Publication Bias
Potential publication bias was evaluated using the 
Eggers’ test and Begg’s funnel plots with log-transformed 
hazards calculated from mOS (horizontal axis) as the out-
come and their SEs (vertical axis) as the index for accuracy 
(Supplementary Figure 1, Supplemental Digital Content 2, 
http://links.lww.com/JTO/A440). The funnel plots were sym-
metrical, with p values of 0.78, 0.17, and 0.21 in the Egger’s 
test for all study arms, CCT− arms, and CCT+ arms, respec-
tively. These data indicate that there is little evidence of pub-
lication bias.
Effects of Study Characteristics on Survival
As our study analyzed potentially heterogeneous study 
arms with different study characteristics, we next examined 
the influence of these study characteristics on mOS. We found 
four characteristics could be implicated in mOS: proportion 
of stage IIIA patients, region and period in which a study was 
conducted, and use of third-generation drugs (Table 2). As 
expected, studies which have larger proportion of stage IIIA 
patients tended to have longer mOS. Studies in Asian countries 
yielded significantly longer mOS (average: 21.2 month) than 
those in non-Asian countries (average: 17.7 months), most 
of which were European countries and the United States. In 
addition, mOS significantly improved during these 15 years: 
16.4 months (1995−2000) versus 19.1 months (2001−2005) 
versus 21.4 months (2006−2011). Furthermore, studies using 
third-generation drugs tended to have longer mOS than those 
using only first- and/or second-generation drugs. Other fac-
tors such as phase II or III or platinum regimens (cisplatin or 
carboplatin) in concurrent phase did not significantly affect 
mOS of study arms (Table 2).
The distribution of study characteristics between 
CCT− and CCT+ is summarized in Supplementary Table 2 
(Supplemental Digital Content 3, http://links.lww.com/JTO/
A441). Although third-generation drugs were more frequently 
used in CCT+ than in CCT−, no significant difference was 
observed in the distribution of other study characteristics 
(Supplementary Table 2, Supplemental Digital Content 3, 
http://links.lww.com/JTO/A441).
No Survival Improvement of LA-NSCLC by CCT
mOS and corresponding 95% CI in each study arm 
are shown in Figure 2. I2 values for assessing heterogene-
ity were 15.3, 31.5, and 36.7 in overall, CCT+, and CCT− 
arms, respectively. No statistical difference was observed 
in the distribution of mOS between CCT+ and CCT− (p = 
0.82). Next, to calculate pooled mOS using random-effects 
TABLE 2.  Impacts of Study Characteristics on mOS
mOS
Study Characteristics No. of Arms No. of Patients Mean SD pa
Trial phase 0.98
  II 34 1936 19.36 5.91 —
  III 11 1543 19.31 4.27 —
Proportion of stage IIIA patientsb 0.046
  ≤33% 22 1674 17.7 3.44 —
  >33% 23 1805 20.9 6.64 —
Period 0.022
  1995–2000 12 738 16.40 3.80 —
  2001–2005 14 978 19.08 4.87 —
  2006–2011 19 1763 21.41 6.15 —
Region 0.035
  Asian 22 1789 21.12 5.97 —
  Non-Asian 23 1690 17.65 4.53 —
Platinum regimens in concurrent phase 0.48
  CDDP 29 2524 18.93 5.77 —
  CBDCA 16 955 20.11 5.08 —
Employment of third-generation drugsc <0.01
  Yes 25 1612 21.12 6.16
  No 20 1867 17.13 3.62
Use of taxanesd 0.33
  Yes 18 1122 20.32 5.26
  No 27 2357 18.70 5.67
aStatistical differences were calculated using Student’s t test or Kruskal–Wallis test across trial arms.
bStudies were divided into two groups with the median by proportion of stage IIIA patients.
cThird-generation drug was defined as irinotecan, paclitaxel, docetaxel, vinorelbine, gemcitabine, pemetrexed, or S-1.
dTaxane was defined as paclitaxel or docetaxel.
CDDP, cisplatin; CBDCA, carboplatin; mOS, median overall survival; SD, standard deviation.
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models, we estimated that survival follows an exponential 
distribution. In this assumption, calculated values of 1-, 2-, 
and 3-year survival rates showed good agreement with actual 
values of them, with minimal bias and acceptable validity 
(Supplementary Figure 2, Supplemental Digital Content 4, 
http://links.lww.com/JTO/A442). In random-effects mod-
els, pooled mOS was comparable between CCT+ (19.0 
month; 95% CI, 17.3−21.0) and CCT− (17.9 month; 95% 
CI, 16.1−19.9), and predicted HR of CCT+ to CCT− was 
0·94 (95% CI, 0.81−1.09; p = 0.40), suggesting that CCT did 
not significantly improve the mOS of LA-NSCLC patients 
(Fig. 2). In addition, pooled 1-, 2-, and 3-year survival rates 
were similar between CCT+ (64.6%, 41.8%, and 27.0%, 
respectively) and CCT− (62.9%, 39.5%, and 24.8%, respec-
tively), supporting the results of mOS analyses. Similar 
results were obtained in the additional meta-regression anal-
ysis adjusted for four study characteristics that could influ-
ence on mOS: proportion of stage IIIA patients, region and 
period, and use of third-generation drugs, (HR: 0.92; 95% CI, 
0.73−1.16; p = 0.29). HRs according to study characteristics 
are shown in Figure 3. CCT did not lead to significant sur-
vival benefit in any subgroups analyzed (period, region, trial 
phase, proportion of stage IIIA patients, use of third-gen-
eration drugs, or use of taxanes). Similarly, significant sur-
vival advantages were not demonstrated in CCCT or SCCT 
compared with CCT− (HR: 0.94; 95% CI, 0.81−1.09; p = 
0.424) and HR: 0.94 (0.71−1.26; p = 0.694), respectively, 
(Supplementary Figure 3, Supplemental Digital Content 5, 
http://links.lww.com/JTO/A443).
Taken Together, Pooled Analyses on Publication 
Data Did Not Support Survival Improvement 
by CCT for Patients with LA-NSCLC
Toxicities
Table 3 summarizes grade 3−5 toxicities reported in the 
study arms. Toxicities throughout the treatment courses were 
comparable between CCT− and CCT+ arms. No significant 
differences were observed in neutropenia, leucopenia, esopha-
gitis, pneumonitis, or treatment-related death.
FIGURE 2.  Individual and pooled median 
overall survivals with corresponding 95% 
CIs in study arms according to the presence 
of CCT. CCT, consolidated chemotherapy; 
CI, confidence interval.
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DISCUSSION
This pooled analysis on published data did not sup-
port the efficacy of CCT in terms of survival prolongation 
for patients with LA-NSCLC. In this study, the combined 
mOS of CCT− studies was 17.9 months, which was compa-
rable with that of CCT+ studies, 19.0 months. In addition, 
the HR of CCT+ to CCT− studies was 0.94. These data sug-
gest that the addition of CCT do not lead to significant sur-
vival prolongation or risk reduction in death for LA-NSCLC 
patients. So far, little is known about the efficacy of CCT 
after concurrent chemo-RT. Previously, three randomized 
trials11,54,55 have been carried out to evaluate the efficacy of 
CCT for LA-NSCLC (254,55 of them have not yet been pub-
lished as full articles), but all of them failed to show sig-
nificant survival benefit in CCT arm (Supplementary Table 
3, Supplemental Digital Content 6, http://links.lww.com/
JTO/A444). Furthermore, we calculated pooled HR using 
the data of these trials in the same methods described in 
Materials and Methods, but no significant survival benefit 
in CCT+ was observed (predicted HR and 95% CI of CCT+ 
to CCT− were 1.03 and 0.71−1.49, respectively). Combined 
with these results, our analysis indicates that there is cur-
rently no sufficient evidence that supports the benefit of CCT 
for LA-NSCLC patients. In clinical practice, however, many 
oncologists still use CCT after concurrent chemo-RT for 
LA-NSCLC. Moreover, in many ongoing trials, CCT is rou-
tinely incorporated, whereas there are few ongoing trials ask-
ing the significance of CCT. Further randomized trials will 
be required to assess the feasibility of using CCT as clini-
cal standard treatment for LA-NSCLC patients. Currently, 
a phase III study is ongoing in Korea to evaluate the CCT 
with cisplatin/docetaxel after concurrent chemo-RT with the 
same agents.4 The outcome of this study is awaited to assess 
the significance of CCT for LA-NSCLC patients.
FIGURE 3.  Hazard ratios of CCT+ to CCT− 
in subgroup analysis according to study 
characteristics. CCT, consolidated chemo-
therapy; CI, confidence interval.
TABLE 3.  Grade 3−5 Toxicities Observed in the Study Arms with and without CCT
Arms without CCT Arms with CCT
Grade 3−5 Toxicities (%) Mean SD Mean SD pa
Neutropenia 50.51 28.42 45.36 24.41 0.63
Leukopenia 58.11 33.11 54.70 22.40 0.74
Esophagitis 14.79 14.68 15.97 12.17 0.78
Pneumonitis 7.97 6.93 7.06 7.30 0.67
Treatment-related death 2.30 2.04 1.96 2.68 0.63
aStatistical differences were calculated using Student’s t test across trial arms.
CCT, consolidation chemotherapy; SD, standard deviation.
1187Copyright © 2013 by the International Association for the Study of Lung Cancer
Journal of Thoracic Oncology ®  •  Volume 8, Number 9, September 2013 Consolidation Therapy for Locally Advanced NSCLC
Toxicities induced by CCT are another concern. In pre-
vious phase III studies, Hanna and colleagues11 reported that 
CCT with docetaxel after concurrent chemo-RT increased 
toxicities including treatment-related death for LA-NSCLC 
patients. In this study, however, no difference was observed in 
toxicities between the two groups. There are several possible 
explanations regarding this discrepancy. First, our analysis 
may not able to detect small differences in toxicities because 
many included studies were not focusing on toxicities in con-
solidation phase. A second possible explanation is that the 
number of delivered courses of CCT was lower than planned 
(Table 1). Third, some chemo-RT regimens used in CCT+ 
group may have less toxicity. For example, weekly paclitaxel 
plus carboplatin with TRT followed by two courses of tri-
weekly paclitaxel plus carboplatin has been reported to be less 
toxic although retaining equivalent efficacy to other full-dose 
chemo-radiation regimens.17 Because of less toxic regimens, 
the toxicities in CCT+ group might have been underestimated. 
As toxicities mostly depend on the menus and delivered doses/
methods of chemotherapy, designs of chemotherapy regimens 
should be carefully considered for future clinical trials.
This study also highlights two more issues. First, studies 
conducted in Asian countries, mostly from Japan and Korea, 
tend to yield longer OS than those in European countries and/
or the United States. The finding may be attributable to the eth-
nic differences between Asian and white patients; an increas-
ing number of publications describe differences in OS and 
toxicity between Asian and white patients with NSCLC.56,57 
However, why survival of Asian patients is longer than that of 
white patients has not been clarified, although it may be in part 
because of the differences among races in tumor behaviors 
arising from somatic mutations or in sensitivities to drugs/
radiation. Of note, the subgroup analyses showed that the HR 
of Asian studies is 0.84 favoring CCT+, though not statisti-
cally significant (p = 0.105; Fig. 3). The result may support 
a possible involvement of ethnicity in the efficacy of CCT. A 
mechanism underlying these ethnic differences may be a clue 
to develop a novel treatment strategy for LA-NSCLC. Second, 
our analyses suggest the improvement in survival outcome of 
LA-NSCLC patients during the past 15 years. However, this 
potential survival improvement during this period needs to be 
assessed with caution, as apparent survival improvement may 
be influenced by stage migration as a result of advancement 
in imaging techniques (e.g., positron emission tomography).58
This study has several limitations. First, because of the 
nature of pooled analyses on a publication basis, our analyses 
included heterogeneous studies with different study designs 
and various patient populations. Although patient characteris-
tics, trial phase, platinum regimens, study period, and region 
of the trials did not significantly differ between CCT+ and 
CCT−, and meta-regression analyses revealed similar results, 
we cannot exclude the possibility that some other differences 
might affect our conclusion. In particular, as our analyses 
were performed on a study basis, they did not cover the het-
erogeneities in individual patient levels. Second, the impacts 
of chemotherapy regimens on survival data also remain to 
be solved. Most studies included in CCT+ were designed 
for CCCT, and only four studies were designed for SCCT; 
therefore, the efficacy of SCCT strategy could not be fully 
evaluated in our analysis, although subset analysis using these 
four SCCT studies did not show significant survival benefit 
by CCT. Similarly, we could not clarify the impact of chemo-
therapy doses on survival, because, in most studies, not full-
dose but low-dose/fractionated chemotherapy was offered in 
the concurrent phase.
Nevertheless, we believe that the findings of this study are 
relevant because we continue to learn how best to tailor treat-
ment for NSCLC patients. Regarding the treatment of stage IV 
NSCLC patients, we have experienced a great advance in the 
last decade; molecular targeted agents and pemetrexed have 
made a major impact in the selected patients, and molecular 
profiling has emerged as central to the treatment.59 In contrast, 
for LA-NSCLC patients, no significant progress in treatment 
strategy has been seen during this decade.60 It seems that we 
have reached a plateau in survival using current chemotherapy 
drugs against LA-NSCLC. Therefore, it is urgent to seek new 
treatment options to improve the prognosis of LA-NSCLC 
patients. Further clinical studies are vital to establish appro-
priate CCT regimens, as well as other novel treatment strate-
gies, which lead to survival prolongation and increase in the 
cure rate of LA-NSCLC patients. Concurrent chemo-RT with 
no CCT would serve as a reference arm in these trials.
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